Celina Ang

Icahn School of Medicine at Mount Sinai

Papers

2

Total Citations

145

H-Index

2

About

Celina Ang is a pioneering clinician-scientist whose work lies at the intersection of precision oncology and rare cancers. She has made groundbreaking contributions to personalized cancer therapy by developing innovative, real-time drug screening platforms. Her landmark 2019 study (107 citations) introduced a personalized platform using patient-derived organoids, or "hindguts," to identify a novel combination therapy—trametinib plus zoledronate—for a patient with KRAS-mutant metastatic colorectal cancer. This robotics-based screen led to a dramatic 11-month partial response, demonstrating the power of tailoring treatments to individual tumor biology. In a subsequent 2021 study (38 citations), she extended this approach to adenoid cystic carcinoma (ACC), a rare salivary gland cancer with limited treatment options. Using a Drosophila-based platform, she identified a personalized therapy for a patient, offering new hope for this challenging disease. Her work not only showcases the potential of functional precision medicine but also provides a scalable framework for treating patients with refractory cancers. Dr. Ang’s research is a testament to the transformative impact of combining innovative technology with compassionate, patient-centered care.

Research Focus

Key Achievements

2
H-Index
2
Papers
145
Total Citations
73
Avg Citations/Paper
🏆 Most Cited Paper
A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer
107 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 31
🏛 Institutions: Icahn School of Medicine at Mount Sinai

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago